| 2025-11-18 |
详情>>
内部人交易：
Chan Phillip P.股份增加100000.00股
|
| 2025-11-13 |
详情>>
股本变动：
变动后总股本6280.43万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.04美元,归母净利润-270.1万美元,同比去年增长78.96%
|
| 2025-11-13 |
财报披露：
美东时间 2025-11-13 盘后发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益0.01美元,归母净利润46.90万美元,同比去年增长104.47%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.02美元,归母净利润-147.84万美元,同比去年增长76.75%
|
| 2025-04-23 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one-year, or until their respective successors are elected, except in the case of the death, resignation or removal of any director;
2.To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K;
3.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2025;
4.To conduct such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-0.38美元,归母净利润-2071.9万美元,同比去年增长27.32%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.24美元,归母净利润-1283.51万美元,同比去年增长43.39%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.19美元,归母净利润-1050.1万美元,同比去年增长22.09%
|
| 2024-08-13 |
详情>>
业绩披露：
2023年中报每股收益-0.31美元,归母净利润-1347.9万美元,同比去年增长32.08%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.12美元,归母净利润-635.79万美元,同比去年增长13.21%
|
| 2024-04-19 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K.
3.To approve an amendment (the “Plan Amendment”) to the Amended and Restated CytoSorbents Corporation 2014 Long-term Incentive Plan.
4.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2024.
5.To conduct such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-03-15 |
详情>>
业绩披露：
2023年年报每股收益-0.64美元,归母净利润-2850.74万美元,同比去年增长13.12%
|
| 2024-03-15 |
详情>>
业绩披露：
2022年年报每股收益-0.75美元,归母净利润-3281.26万美元,同比去年增长-33.61%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.52美元,归母净利润-2267.25万美元,同比去年增长29.25%
|
| 2023-04-21 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K;
3.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2023;
4.To conduct such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2022-04-22 |
股东大会：
将于2022-06-07召开股东大会
会议内容 ▼▲
- 1.To elect six directors, who shall each serve for a term of one year;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K;
3.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2022;
4.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-19 |
股东大会：
将于2021-06-01召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K;
3.To determine, on an advisory basis, the frequency with which the stockholders of the Company shall have an advisory vote on executive compensation, as disclosed pursuant to the executive compensation disclosure rules of the Securities and Exchange Commission
4.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2021;
5.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2020-04-20 |
股东大会：
将于2020-06-02召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year;
2.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2020;
3.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2019-04-22 |
股东大会：
将于2019-06-04召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year;
2.To authorize our Board of Directors, in its discretion, to amend and restate the First Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Incorporation”) to increase the total number of authorized shares of common stock, par value $0.001 per share (“Common Stock”) from 50,000,000 to 100,000,000;
3.To approve an amendment and restatement of the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the “2014 Long-Term Incentive Plan,” or “Plan”);
4.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent auditors to audit the Company’s financial statements for the fiscal year ending December 31, 2019;
5.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2018-04-25 |
股东大会：
将于2018-06-05召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year,
2.To approve the compensation of the Company’s named executive officers, on an advisory basis,
3.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent auditors to audit the Company’s financial statements for the fiscal year ending December 31, 2018,
4.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2017-04-27 |
股东大会：
将于2017-06-06召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year,
2.To approve an amendment and restatement of the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the “2014 Long-Term Incentive Plan” or “Plan”),
3.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent auditors to audit the Company’s financial statements for the fiscal year ending December 31, 2017,
4.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2016-04-25 |
股东大会：
将于2016-06-07召开股东大会
会议内容 ▼▲
- 1.To elect five directors, who shall each serve for a term of one year,
2.To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent auditors to audit the Company’s financial statements for the fiscal year ending December 31, 2016,
3.To conduct such other business as may properly come before the Annual Meeting or any adjournments thereof.
|